Karuna Therapeutics Inc
Change company Symbol lookup
Select an option...
KRTX Karuna Therapeutics Inc
SNSE Sensei Biotherapeutics Inc
ALGS Aligos Therapeutics Inc
SRRA Sierra Oncology Inc
ATOS Atossa Therapeutics Inc
OSMT Osmotica Pharmaceuticals PLC
SAND Sandstorm Gold Ltd
GRVI Grove Inc
STON Stonemor Inc
TK Teekay Corp
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Karuna Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on to create and deliver transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate, KarXT, is an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. It is initially developing KarXT, for the treatment of acute psychosis in patients with schizophrenia. The Company is developing a pipeline of therapeutic programs to address symptoms associated with schizophrenia and psychosis associated with Alzheimer’s disease (AD), as well as various forms of pain. KarXT is a combination of xanomeline and trospium. KarXT combines xanomeline, a muscarinic agonist, with trospium, a muscarinic antagonist, to stimulate muscarinic receptors in the CNS. It is advancing a pipeline of therapeutic programs to address the positive, negative and cognitive symptoms.

Price
Delayed
$123.87
Day's Change
-0.74 (-0.59%)
Bid
--
Ask
--
B/A Size
--
Day's High
125.49
Day's Low
121.22
Volume
(Light)

Today's volume of 27,849 shares is on pace to be much lighter than KRTX's 10-day average volume of 191,081 shares.

27,849

Albemarle Corp. Stock Underperforms Friday When Compared To Competitors

4:35 pm ET October 1, 2021 (MarketWatch)
Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Albemarle Corp. (ALB) slipped 0.04% to $218.89 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index rising 1.15% to 4,357.04 and the Dow Jones Industrial Average rising 1.43% to 34,326.46. Albemarle Corp. closed $34.21 short of its 52-week high ($253.10), which the company achieved on September 10th.

The stock demonstrated a mixed performance when compared to some of its competitors Friday, as W.R. Grace & Co. (GRA) rose 0.03% to $69.99, Avient Corp. (AVNT) rose 1.42% to $47.01, and BASF SE ADR (BAS.XE) fell 0.84% to $18.88. Trading volume (1.1 M) remained 221,500 below its 50-day average volume of 1.3 M.

Data source: Dow Jones Market Data, FactSet. Data compiled October 1, 2021.

-MarketWatch Automation

	

(END) Dow Jones Newswires

October 01, 2021 16:35 ET (20:35 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.